Latest Conference Articles

Having knowledge that their multiple myeloma was incurable was associated with poor quality of life outcomes in patients.

The XVd regimen appears effective at prolonging progression-free survival with decreased toxicity when administered at lower doses of selinexor or the standard dose.

Polatuzumab vedotin-piiq added to the R-CHOP regimen elicited a high progession-free survival rate in patients with newly-diagnosed diffuse large B-cell lymphoma.

An RMAT designation granted to FT516 is supported by data from a phase 1 trial of FT516 in patients with diffuse large B-cell lymphoma.

Updated results from CARTITUDE-1 reveal deep and durable response to ciltacabtagene autoleucel treatment in patients with multiple myeloma.

Preliminary results from the phase 2 ERADIC trial signal promise for ibrutinib plus venetoclax for the treatment of chronic lymphocytic leukemia.

An early and deep response was seen with a single infusion of cilta-cel in patients with multiple myeloma who experienced early clinical relapse.

In patients with relapsed/peripheral T-cell lymphoma, the combination of duvelisib plus romidepsin was shown to be highly active.

While Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma, adverse events were common in some of these populations.

In patients with relapsed/refractory multiple myeloma with t(11;14), Selinexor plus venetoclax induced decreases in cyclin D1, XPO1, and MCL-1.

Compared to those who received rituximab and bendamustine, elderly patients treated with ibrutinib-containing regimens for chronic lymphocytic leukemia saw a progression-free survival benefit.

Durable responses and tolerability for patients was seen with itolizumab for acute graft-versus-host disease.

Lisocabtagene maraleucel treatment in patients with relapsed or refractory B-cell lymphoma achieves long-lasting responses, study shows.

The costs of treatment and time spent managing adverse effects varied significantly in patients with chronic lymphocytic leukemia treated with acalabrutinib, ibrutinib, and venetoclax.

Jennifer R. Brown, MD, PhD, discusses the implications of the SEQUOIA trial, which looked at the combination of zanubrutinib and venetoclax for the treatment of patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.

The efficacy and safety of naratuximab emtansine plus rituximab appear impressive for patients with B-cell non-Hodgkin lymphomas who are ineligible for stem cell transplant or chimeric antigen receptor T-cell therapy.

Undetectable minimal residual disease may be achieved with time-limited ublituximab and umbralisib added to ibrutinib in patients with chronic lymphocytic leukemia.

Phase 3 ZUMA-7 study results indicate that axicabtagene ciloleucel may achieve longer event-free survival compared with standard chemotherapy.

A CARTITUDE-1 meta-analysis data shows that ciltacabtagene autoleucel performs better than standard-of-care therapy in terms of survival and response rates in patients with triple-class relapsed/refractory multiple myeloma.

Results from the phase 2 IFM 2018-01 trial show positive safety and efficacy for the combination of daratumumab with ixazomib, lenalidomide, and dexamethasone.

Analysis shows that International Prognostic Scoring System score and the presence of a JAK2 mutation was linked to risk of thrombosis in patients with primary myelofibrosis. Investigators observed a benefit for ruxolitinib in patients.

Minimum residual disease can inform approaches to treatment of newly diagnosed multiple myeloma for patients receiving daratumumab plus carfilzomib, lenalidomide, and dexamethasone following autologous transplant.

Axicabtagene ciloleucel demonstrated a quality of life improvement in patients with large B-cell lymphoma as a second-line treatment compared with standard of care.

In a randomized phase 3 trial, acalabrutinib plus venetoclax versus obinutuzumab plus venetoclax will be investigated for efficacy and safety with a noninferiority design in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic leukemia.

Chemotherapy with the addition of eryaspase showed biological efficacy in reducing hypersensitivity reactions to asparaginase in patients with acute lymphoblastic leukemia.

Findings from the phase 3 ASCEMBL trial showed a consistent improvement in major molecular response rate and depth of response without any new or worsening adverse effects when treating with asciminib versus bosutinib in patients with chronic-phase chronic myeloid leukemia.

Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety.

Older patients with diffuse large B-cell lymphoma experienced improved progression-free survival, quality of life, and function after receiving ibrutinib plus rituximab and mini-CHOP.

Patients with late- and early-relapsed multiple myeloma receiving the combination of selinexor plus daratumumab, bortezomib, and dexamethasone showed promising efficacy and a manageable safety profile.

Patients with relapsed/refractory chronic lymphocytic leukemia experienced progression-free survival benefit with acalabrutinib versus the standard of care, and therapy was effective out to 3 years in the ASCEND trial.